TY - JOUR
TI - Fetal subependymal giant cell astrocytoma: A case report and review of the literature
AU - Karagianni, A.
AU - Karydakis, P.
AU - Giakoumettis, D.
AU - Nikas, I.
AU - Sfakianos, G.
AU - Themistocleous, M.
JO - Surgical Neurology International
PY - 2020
VL - 11
TODO - 26
SP - null
PB - SCIENTIFIC SCHOLAR LLC
SN - null
TODO - 10.25259/SNI_10_2019
TODO - everolimus;  glial fibrillary acidic protein;  protein S 100;  vigabatrin, angiomyolipoma;  calcification;  cancer patient;  cancer surgery;  case report;  cell differentiation;  choroid plexus papilloma;  clinical article;  craniotomy;  electroencephalogram;  female;  fetus;  focal epilepsy;  follow up;  gestational age;  human;  immunofluorescence;  immunohistochemistry;  macrophage;  microglia;  mortality;  nuclear magnetic resonance imaging;  pediatric patient;  physical examination;  postoperative period;  priority journal;  psammoma body;  Review;  subependymal giant cell astrocytoma;  surgical patient;  tuberous sclerosis;  tumor volume
TODO - Background: Subependymal giant cell astrocytomas (SEGAs) appear approximately in 10% of patients with tuberous sclerosis. These tumors are most commonly diagnosed in childhood and adolescence, with in utero diagnosed SEGAs being an extremely rare entity. Case Description: We present the case of a congenital SEGA detected in an antenatal ultrasound and further investigated with fetal magnetic resonance imaging (MRI) scans at 22 and 32 weeks of gestational age. At 9 days of age, the child underwent craniotomy and partial excision of the tumor, followed by a second more extensive operation 13 days later. The patient was subsequently administered mammalian target of rapamycin inhibitor (everolimus). Conclusion: In the latest follow-up MRI, at the age of two, the SEGA remained unchanged. Management of these tumors in neonates is challenging, mainly due to high morbidity and mortality of surgical treatment in these ages. © 2020 Scientific Scholar. All rights reserved.
ER -